T. Rowe Price Associates
KYMR icon

T. Rowe Price Associates’s Kymera Therapeutics KYMR Stock Holding History

T. Rowe Price Associates’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$816M Buy
7,112,980
+1,052,133
+17% +$90.4M 0.08% 196
2026
Q1 		$505M Sell
6,060,847
-98,488
-2% -$7.8M 0.06% 251
2025
Q4 		$479M Buy
6,159,335
+1,061,957
+21% +$71.7M 0.05% 275
2025
Q3 		$289M Sell
5,097,378
-1,761,824
-26% -$79.5M 0.03% 371
2025
Q2 		$299M Buy
6,859,202
+156,752
+2% +$5.4M 0.03% 354
2025
Q1 		$183M Sell
6,702,450
-167,883
-2% -$6.12M 0.02% 442
2024
Q4 		$276M Buy
6,870,333
+224,859
+3% +$10.2M 0.03% 367
2024
Q3 		$315M Buy
6,645,474
+254,816
+4% +$11.3M 0.04% 353
2024
Q2 		$191M Buy
6,390,658
+58,646
+0.9% +$2.03M 0.02% 425
2024
Q1 		$255M Buy
6,332,012
+996,300
+19% +$35.6M 0.03% 381
2023
Q4 		$136M Buy
5,335,712
+278,287
+6% +$4.98M 0.02% 491
2023
Q3 		$70.3M Buy
5,057,425
+50,277
+1% +$1.01M 0.01% 588
2023
Q2 		$115M Buy
5,007,148
+340,467
+7% +$9.76M 0.02% 502
2023
Q1 		$138M Buy
4,666,681
+287,522
+7% +$9.27M 0.02% 458
2022
Q4 		$109M Buy
4,379,159
+281,447
+7% +$7.5M 0.02% 473
2022
Q3 		$89.2M Sell
4,097,712
-1,126,974
-22% -$29.7M 0.01% 508
2022
Q2 		$103M Buy
5,224,686
+1,329,481
+34% +$31.1M 0.01% 650
2022
Q1 		$165M Buy
3,895,205
+344,677
+10% +$14.6M 0.02% 589
2021
Q4 		$225M Buy
3,550,528
+317,331
+10% +$18.5M 0.02% 528
2021
Q3 		$190M Buy
3,233,197
+1,388,271
+75% +$80.5M 0.02% 561
2021
Q2 		$89.5M Buy
1,844,926
+911,948
+98% +$39.6M 0.01% 826
2021
Q1 		$36.3M Buy
932,978
+540,902
+138% +$32.6M ﹤0.01% 1115
2020
Q4 		$24.3M Buy
392,076
+97,381
+33% +$4.75M ﹤0.01% 1174
2020
Q3 		$9.52M Buy
+294,695
New +$9M ﹤0.01% 1311

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's KYMR Position: Q2 2026 in Review

T. Rowe Price Associates increased its Kymera Therapeutics (KYMR) stake by 17% in Q2 2026, buying an estimated $90.4M and bringing the position to 7,112,980 shares worth $816M. The position accounts for 0.08% of the portfolio, ranked #196.

T. Rowe Price Associates first reported a position in KYMR in Q3 2020 and has held it in 24 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • T. Rowe Price Associates held 7,112,980 shares of Kymera Therapeutics worth $816M as of Q2 2026.
  • T. Rowe Price Associates bought 1,052,133 Kymera Therapeutics shares in Q2 2026, an estimated $90.4M.
  • Kymera Therapeutics made up 0.08% of T. Rowe Price Associates's portfolio in Q2 2026, its #196 holding.
  • T. Rowe Price Associates first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.